Boudicca Dx, LLC.

Kelly Gordon, Ph.D., MB, CEO,

Dr. Gordon has worked in the oncology field for over 20 years and the diagnostics industry for over 10 years developing innovative biomarker and diagnostic testing products. Dr. Gordon has experience working in both diagnostic and therapeutic companies driving the product development and regulatory strategy for high-value companion diagnostic assays, which include the multi-indication PD-L1 immunohistochemistry assays launched by Roche for the cancer immunotherapy TECENTRIQ and the pan-cancer genomics testing strategy for Loxo Oncology's VITRAKVI. Dr. Gordon runs a consulting firm Boudicca Dx., LLC. supporting clients with their biomarker testing and companion diagnostics strategies. Dr. Gordon received her B.S. in Molecular and Cellular Biology from the University of Arizona, Ph.D. in Pharmacology from Duke University, and completed post-doctoral training in Cancer Biology at the Translational Genomics Research Institute and Arizona Cancer Center. Dr. Gordon has hands-on experience analytically and clinically validating tests spanning genomic, proteomic and transcriptomic technologies. Dr. Gordon knows the regulatory pathways for clinical trial assays and *in vitro* diagnostics and has direct experience developing tests in accordance with CAP, CLIA, NYS-DOH, EU (IVDR), and US-FDA regulations. Dr. Gordon has led regulatory submissions and interactions to support both the investigational use (in clinical trials) and marketing of tests.